Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

2 items

Reflex testing on newly diagnosed tumours with advanced/metastatic urothelial carcinoma.

Funded Biomarker Disease Site: Bladder/ Urothelial

Biomarker: FGFR2, FGFR3

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.

Funded Biomarker Disease Site: Bladder/ Urothelial

Biomarker: MLH1, MSH2, MSH6, PMS2

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System